|
Title
|
Publication Date
|
Price
|
Relevance
|
|
CSL Limited-Detailed Product Pipeline
|
Mar 2011 |
£475 |
100% |
|
CSL Limited-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
99% |
|
CSL Limited-Deals & Alliances Report
|
Mar 2011 |
£380 |
99% |
CSL Limited – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
97% |
|
CSL Ltd - Financial and Strategic Analysis Review
|
Apr 2009 |
£79 |
90% |
Top 10 Biotechnology Companies
SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline
|
Feb 2010 |
£2,215 |
89% |
|
H1N1 Vaccines
|
Apr 2010 |
£2,500 |
85% |
Hemophilia Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
80% |
Biotechnology Industry 2010 Yearbook
Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
|
Dec 2010 |
£2,215 |
79% |
Hemophilia A Global Clinical Trials Review
H2, 2011
|
Oct 2011 |
£630 |
79% |
Rabies Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
78% |
Patrys Limited – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
78% |
|
Research Report on Global and Chinese Blood Product Industry, 2009
|
Mar 2009 |
£1,010 |
77% |
Hemophilia - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
76% |
Blood Banking and Blood Products
Global Market Perspective
|
Nov 2009 |
£1,895 |
76% |
Angioedema Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
75% |
Von Willebrand Disease - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
75% |
H1N1 (Swine Influenza)
Pipeline Assessment and Market Forecasts to 2017
|
Mar 2011 |
£1,265 |
75% |
|
Blood Banking & Blood Products
|
Oct 2008 |
£2,500 |
75% |
Stakeholder Opinions: Tropical Diseases
Dengue, Japanese encephalitis and West Nile virus – Increasing attention for neglected diseases
|
Dec 2010 |
£2,405 |
74% |
Hemophilia B - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
74% |
Hemophilia B Global Clinical Trials Review
H2, 2011
|
Aug 2011 |
£630 |
73% |
Influenza Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
73% |
Emphysema Global Clinical Trials Review
H2 2011
|
Oct 2011 |
£630 |
73% |
|
The Global Influenza Market
|
Aug 2009 |
£3,065 |
73% |
|
Blood Banking and Blood Products
|
Sep 2010 |
£2,845 |
72% |
Research Report on Global and China's Blood Products Industry
2011-2012
|
Feb 2010 |
£1,390 |
72% |
Critical Care Market to 2017
Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles
|
Sep 2011 |
£2,215 |
72% |
Hemophilia A - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
72% |
|
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
Mar 2010 |
£3,065 |
71% |
